Sure, the UK approval helps, but ultimately its all about execution. Markets are forward looking. And no trusts this team to deliver value along these lines. When a company takes 4.5 years to get approval in a small market without reimbursement support for another year at the very least, it prevents prospective investors from taking a bet. Thus, it will be another dump at the UK approval spike.
No hiring is another indication they are not prepared to deliver post UK approval. Biotechs start building sales and marketing team 6-9 months in advance. Hiring process starts almost a year in advance. Even small biotechs, the size of NWBO, start hiring couple of quarters in advance.
They are well positioned to disappoint post UK approval. No wonder shorts won’t leave the company alone because they know that this company is going nowhere and its easy money for them at the expense of LP and the bag-holders.
Market Data 
Markets 
AI
